BRIEF—C2 Pharma plans new launches and filings

Irish ophthalmic and active pharmaceutical ingredient (API) specialist C2 Pharma has announced plans to expand its API  product portfolio.

The firm has new launches and regulatory filings planned in both Europe and the USA for November 2022.

Company filings have been completed with the US regulator to switch the ownership for three drug master files of the ophthalmic APIs brimonidine, latanoprost and bimatoprost.

The company is also expanding into Asia and South America, with new filings including for products cyclopentolate hydrochloride, brimonidine tartrate, latanoprost and bimatoprost.